CD68 and rheumatoid arthritis: Conversely, naïve Abneg RA patients who reached the DAS remission status at 6 months follow-up had lower sublining CD68+ cell IHC score (0.92 ± 0.58) before methotrexate beginning, compared to naïve Abneg RA patients who did not achieved the clinical endpoint at 6 months (2.13 ± 0.55; p < 0.001) (Table 2).